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Prophylactic Mastectomy in Carriers 
of 
 
BRCA
 
 Mutations
 
To the Editor: 
 
At first glance, the data of Meijers-Heij-
boer and colleagues (July 19 issue)
 
1
 
 appear to support the
position that prophylactic mastectomy reduces the risk of
breast cancer in carriers of a 
 
BRCA
 
 mutation. On close read-
ing of the article, however, I find that very little support
for this position is presented. The authors report no new
cases of breast cancer after a mean of 2.9 years in a cohort
of 76 women who underwent mastectomy. This is to be ex-
pected, however; no breast cancers were detected on patho-
logical review of the corresponding specimens, and it is ex-
ceedingly unlikely that a submicroscopic breast cancer will
present as a chest-wall primary tumor or as metastatic dis-
ease within three years.
In a short-term follow-up study, it is perhaps possible to
study whether or not preclinical breast cancers that are iden-
tified by pathological review are cured, but the investigators
found no cancers. This is probably due to the small sample,
the use of premastectomy screening examinations, and the
high frequency of previous oophorectomy in the mastecto-
my group (58 percent). Oophorectomy prior to menopause
reduces the incidence of breast cancer by 70 percent in
carriers of a 
 
BRCA1
 
 mutation.
 
2
 
My colleagues and I recently used magnetic resonance
imaging (MRI) to perform screening examinations in 96
asymptomatic women with a 
 
BRCA
 
 mutation and detected
five invasive breast cancers (prevalence, 5.2 percent) in this
group.
 
3
 
 To evaluate the ultimate effectiveness of MRI, it will
be necessary to establish whether these women are eventu-
ally cured of their disease. If our figures are correct, then
in the study by Meijers-Heijboer et al. there should have
been four breast cancers among the women in the mastec-
tomy group, and it is perhaps not surprising that none of
these cancers were detected. But if the study was too small
to allow detection of any breast cancers at the initial patho-
logical review, then it was too small to evaluate the effective-
ness of mastectomy as a prophylactic measure over the short
term. At the Centre for Research in Women’s Health at the
University of Toronto, I have prospectively studied a cohort
of 61 carriers of a 
 
BRCA
 
 mutation after prophylactic mas-
tectomy for a mean follow-up period of three years and have
collected data on new cancers in this cohort. I intend to
submit the data for publication when the results are inter-
pretable.
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To the Editor:
 
 In the article by Meijers-Heijboer et al., a
10-to-15-year mortality rate of 35 to 50 percent is project-
ed for those whose hereditary breast cancers are diagnosed
by surveillance. Since the authors state that the prognosis
of 
 
BRCA
 
-associated tumors is no different than that of non–
 
BRCA
 
-associated tumors, the poor outcome they project for
women who choose surveillance must be due to the stage
of the cancers in carriers of a 
 
BRCA
 
 mutation. However, in
contrast to the 50 percent rate of lymph-node metastasis
in this study, other studies have reported a 21 percent rate:
in two separate MRI series involving a combined total of
375 women at hereditary risk for breast cancer, only 4 of 19
detected breast tumors were lymph-node positive.
 
1,2
 
 The 25
percent 10-year risk of breast cancer assumed in the current,
clinic-based series is also higher than the rate we and oth-
ers have derived from ascertainments not biased by family
history.
 
3
 
Varying these two assumptions would result in a sub-
stantially lower projected mortality in women undergoing
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risk-reducing mastectomy as compared with surveillance.
Even assuming a 10-year incidence of breast cancer of 25
percent, 75 percent of the women who opt for preventive
surgery would not have breast cancer during this period.
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To the Editor:
 
 Meijers-Heijboer et al. found no instance
of breast cancer after prophylactic bilateral mastectomy
among 76 women followed for 219 women-years at risk.
An exponential model was used to estimate the annual risk
among 63 other women, who chose to remain under sur-
veillance and were followed for 190 women-years; in this
group, eight cases of breast cancer developed, and the an-
nual rate of breast cancer was estimated at 2.5 percent. No
estimate was given for the prophylactic-mastectomy group.
Unfortunately, the finding of zero cases does not imply
that the risk is zero.
 
1
 
 The data are compatible with a very
small annual risk not detectable during 219 women-years
of follow-up. An estimate of the upper limit of the annual
risk can be made by using an exponential model (with a con-
stant hazard rate), assuming independence of the events, and
specifying the desired power. At a power of 0.80, 0.90, or
0.95, the respective upper limits are 0.73 percent, 1.05 per-
cent, and 1.36 percent per year. To compare these estimates
with that in the surveillance group, we also must assume
that our ability to detect breast cancer (i.e., the sensitivity
of our methods of detection) is the same for both groups.
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To the Editor:
 
 In their article on prophylactic mastectomy
in women with a 
 
BRCA1
 
 or 
 
BRCA2
 
 mutation, Meijers-
Heijboer and colleagues “estimate that 10 to 20 percent
of women who choose surveillance will die of breast can-
cer within 20 years.” Our own recent findings
 
1
 
 and those
of others
 
2,3
 
 suggest that the inclusion of MRI in surveil-
lance programs will allow earlier detection of breast cancer
in such women. This approach will most likely result in a
lower mortality than the estimate that Meijers-Heijboer and
colleagues make. In studies that compare the efficacy of op-
tions open to women with a hereditary risk of breast can-
cer, the addition of MRI to the surveillance program of
each woman is therefore essential.
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The authors reply:
 
To the Editor: 
 
The aim of our study was not to investigate
the process of tumor progression, as suggested by Narod,
but to estimate the reduction of risk by prophylactic mas-
tectomy in healthy women with a 
 
BRCA1
 
 or 
 
BRCA2 
 
mu-
tation as compared with that in similar women who opted
for surveillance after the possibility of an existing tumor
was ruled out (one woman was found to have breast can-
cer at the first screening and was excluded from the study).
This risk reduction appeared to be significant, even after
adjustment for past oophorectomy. Because all the women
underwent premastectomy screening examinations to rule
out breast cancer, it was not surprising that only one car-
cinoma in situ was found in the specimens obtained at the
time of mastectomy. The series of women with a 
 
BRCA1
 
 or
 
BRCA2
 
 mutation in the MRI study conducted by Narod’s
group
 
1
 
 cannot be compared with our series. The women
in their series were older and had a different spectrum of
 
BRCA1
 
 and 
 
BRCA2 
 
mutations; 34 (35 percent) had a his-
tory of breast cancer (four of the seven cancers detected
were found in the contralateral breast of affected women);
29 percent had not undergone screening mammography
within the previous 15 months; the number of new cancers
was unclear; and the median follow-up was very short (1
 
1
 
⁄
 
2
 
years or less).
As suggested by Offit et al., the risk in women in pop-
ulation studies might differ from that in women with a
family history. However, because in our family cancer clinic
we see mainly women who are worried by their family his-
tory, we decided not to enter into a discussion of data
from population studies.
The clinical outcome we projected for the women who
chose surveillance was based not only on stage but also on
their young age and on the unfavorable pathological char-
acteristics of 
 
BRCA1
 
-associated breast cancers. Previously
we reported a 50 percent death rate after 10 years in wom-
en with primary breast cancer who had either a 
 
BRCA1
 
mutation
 
2
 
 or a 
 
BRCA2 
 
mutation.
 
3
 
 In addition, in a series
of 1198 women at high risk, we found that the screening
results were worse in women in the youngest age category
and in those with a 
 
BRCA1
 
 or 
 
BRCA2 
 
mutation than in
women in other subgroups.
 
4
 
We agree with Offit et al. and Stoutjesdijk and Barentsz
that the application of sensitive MRI methods in a stand-
ard surveillance program might improve survival, but hard
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data are lacking. Finally, we thank Riggs for his interesting
calculations and agree that encountering zero cases does
not imply that the risk is zero, as indicated by the 95 per-
cent confidence interval of 0 to 0.36 in our report.
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Treatment of Hairy-Cell Leukemia
 
To the Editor:
 
 Kreitman et al. (July 26 issue)
 
1
 
 report that
an anti-CD22 recombinant immunotoxin (BL22) induced
complete remissions in 11 of 16 patients with hairy-cell
leukemia that was resistant to cladribine. Although BL22
represents an exciting new approach to the treatment of this
disease, the results need to be interpreted cautiously, given
the potential life-threatening toxicity of this agent (the he-
molytic–uremic syndrome developed in two patients).
When a single course of cladribine was administered by
continuous intravenous infusion for seven days to 349 pa-
tients with hairy-cell leukemia at Scripps Clinic, 319 pa-
tients (91 percent) had an initial complete response, and 22
(6 percent) had a partial response.
 
2 
 
Ninety patients (26 per-
cent) relapsed after a median of 29 months. Of 53 patients
treated with second courses of cladribine at the time of the
first relapse, 33 (62 percent) had complete responses, and
14 (26 percent) had partial responses. Thus, cladribine re-
sistance in patients with hairy-cell leukemia is indeed a rare
occurrence. Kreitman et al. should therefore clarify their def-
inition of cladribine resistance as “an inadequate response.”
Also, despite the structural and mechanistic homology be-
tween cladribine and pentostatin (2'-deoxycoformycin),
cladribine induced durable complete responses in patients
with hairy-cell leukemia that was truly resistant to pento-
statin, suggesting the absence of cross-resistance between
these two agents.
 
3
 
The 16 patients of Kreitman et al. had hairy-cell leuke-
mia with an unusual resistance to systemic chemotherapy.
The features predicting this resistance were the marked lym-
phocytosis in five patients, the abdominal masses in two pa-
tients, and the aberrant display of CD antigens in three pa-
tients.
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The authors reply:
 
To the Editor: 
 
All 16 patients with hairy-cell leukemia in
our study had an inadequate response to their last treatment
with cladribine. Two had brief complete remissions that
lasted 4 and 15 months. The other 14 patients had a partial
response or no response to the last course of cladribine, and
in only 1 of them was the cytopenia corrected. Five pa-
tients had no response to the first course of cladribine, an
unusual finding in patients with hairy-cell leukemia, where-
as 11 patients had resistance to cladribine after one to five
relapses, a more typical finding. We agree with Saven that
cladribine is associated with a high rate of complete remis-
sion in patients who have not previously been treated and
in those with a first relapse, but almost 5 percent of pa-
tients have no response or have persistent cytopenia after
their first course of cladribine.
 
1
 
 Furthermore, the rate of
complete remission and the time to treatment failure de-
crease with subsequent courses of the drug, and there is
no plateau in disease-free or overall survival.
 
2-4
 
Long-term follow-up data after three or more courses
of cladribine have not been published. The median follow-
up in the study cited by Saven was 58 months, and the study
ended in mid-1987.
 
1
 
 No other trial has reported longer
follow-up data. In contrast, our patients were enrolled a
median of eight years after diagnosis, and most had received
other treatments in addition to cladribine. The 11 patients
in our study who had received more than one course of
cladribine began BL22 treatment 2 to 10 years (median, 7)
after the first course of cladribine.
We believe that BL22 is a potentially important investi-
gational therapy for cladribine-resistant hairy-cell leukemia,
since it produces complete remission without irreversible
toxicity.
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Management of Tuberculosis
To the Editor: When discussing indications for the treat-
ment of latent tuberculosis infection, Small and Fujiwara
(July 19 issue)1 follow the joint statement of the American
Thoracic Society and the Centers for Disease Control and
Prevention (CDC)2 in considering patients regardless of age.
Prior guidelines did not recommend routine treatment for
those older than 35 years, the point at which isoniazid
hepatotoxicity was thought to be more likely to occur than
disease reactivation.3 Is age no longer a concern? For exam-
ple, since treatment is now recommended for all tuberculin-
positive persons who have emigrated from high-prevalence
areas to the United States within the preceding five years,
should we prescribe isoniazid to a recently arrived 75-year-
old person? Should we withhold therapy from a 26-year-old
who came to the United States at the age of 19?
Small and Fujiwara also recommend initial two-step test-
ing for persons who are likely to have serial tuberculin tests,
to avoid confusion from future false positive “conversions”
caused by the booster phenomenon. As they note, such
results imply waning immunity from infections acquired in
the distant past. Yet the CDC recommends that all newly
employed health care workers receive two-step testing if
they lack proof that they have had a negative skin test within
the preceding 12 months,4 despite the added expense and
inconvenience. Is this step required for low-risk employ-
ees? What if one had a negative skin test two or three years
previously? Would a 25-year-old employee who had been
born in a high-prevalence area even require two-step test-
ing, since the booster phenomenon is rare at this age?
STEVEN LEINER, N.P., P.A.-C.
Mission Neighborhood Health Center
San Francisco, CA 94110
sleiner@itsa.ucsf.edu
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1994;149:1359-74.
4. Guidelines for preventing the transmission of Mycobacterium tuberculosis 
in health care facilities, 1994. MMWR Morb Mortal Wkly Rep 1994;
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To the Editor: Small and Fujiwara mention the possibility
of eliminating tuberculosis in the United States. For this
to become a reality, however, “hot spots” of tuberculosis,
especially in the South and in urban areas, will need to be
addressed by public health officials. Nearly all southeastern
states continue to have rates of tuberculosis that are higher
than the national average, with most cases occurring among
U.S.-born persons, most frequently blacks.1,2 In Georgia,
the number of cases of tuberculosis has increased in the past
two years.1 The rates of disease in some areas of Atlanta
exceed 100 cases per 100,000 persons per year,3 similar to
the rates in developing countries.
The racial disparity is also striking, with rates that are
12 times as high among blacks as among whites. This high
burden of disease greatly affects Grady Memorial Hospital,
where active tuberculosis was diagnosed in 139 patients (a
third of whom were coinfected with the human immunode-
ficiency virus) in 2000, for a rate of 496 cases per 100,000
admissions (Table 1). During the past decade, if Grady
Memorial Hospital had been a state, it would have ranked
28th in the country in terms of the number of cases re-
ported.3 Tuberculosis is not a Medicaid-eligible disease in
Georgia (as it is in all of the other high-incidence states);
thus, the hospital has annually provided more than $1.5 mil-
lion of uncompensated care to patients with tuberculosis.
Adequate resources for care, public health control, and
research on interventions to interrupt the transmission of
Mycobacterium tuberculosis in hot spots are much needed
and will be required if we are serious about eliminating tu-
berculosis in the United States.
HENRY M. BLUMBERG, M.D.
CARLOS DEL RIO, M.D.
Emory University School of Medicine
Atlanta, GA 30303
hblumbe@emory.edu
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2894-900.
3. Sotir MJ, Parrott P, Metchock B, et al. Tuberculosis in the inner city: 
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To the Editor: In their otherwise excellent review of tu-
berculosis, Small and Fujiwara did not adequately address
the difficult subject of the use of rifampin with nonnucle-
oside reverse-transcriptase inhibitors. There is no change in
rifampin levels when it is given with either of the two most
commonly prescribed nonnucleoside reverse-transcriptase
inhibitors, nevirapine and efavirenz.1,2 Small and Fujiwara
appropriately note that delavirdine and nevirapine, the first
two of these agents to be approved by the Food and Drug
*Data are from the Centers for Disease Control
and Prevention.1
TABLE 1. CASES OF TUBERCULOSIS REPORTED 
IN THE UNITED STATES, GEORGIA, AND 
GRADY MEMORIAL HOSPITAL IN ATLANTA.
YEAR
UNITED 
STATES* GEORGIA*
GRADY 
MEMORIAL 
HOSPITAL
number of cases
1996 21,337 791 175
1997 19,851 691 175
1998 18,361 636 142
1999 17,531 665 148
2000 16,377 703 139
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Administration, are not recommended for use with rifam-
pin because rifampin can significantly lower serum levels
of these antiretroviral agents. However, rifampin reduces
the area under the curve, minimal concentration, and max-
imal concentration of efavirenz, the most recently approved
nonnucleoside reverse-transcriptase inhibitor, by less than
30 percent in all studies published to date.2,3 Hence, many
experts recommend the combination of rifampin and efa-
virenz, with an increase in the dose of efavirenz to 800 mg
per day, for the treatment of patients with tuberculosis who
require antiretroviral therapy.2,3 One small study even com-
pared a regimen of efavirenz and rifampin with a regimen
of rifampin alone and found that both regimens were highly
efficacious.4
LORI E. FANTRY, M.D., M.P.H.
University of Maryland Medical School
Baltimore, MD 21201
lfantry@medicine.umaryland.edu
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To the Editor: Small and Fujiwara state that evaluation of
urine for discoloration can be used to assess compliance in
patients who are taking rifampin for tuberculosis. Because
of its pharmacokinetics, isoniazid is also suitable for use in
an assessment of compliance. The “Arkansas method” for
the detection of isoniazid allows compliance to be assessed
even if patients took the drug up to 24 hours before their
arrival at the clinic.1,2 The peak of the rifampin-induced or-
ange coloration of the urine occurs six hours after the in-
gestion of the drug. This test lacks specificity and sensitivity
if it is performed more than 12 hours after the ingestion
of rifampin.3 The Arkansas method has equally good results
with the use of commercially available paper strips (Taxo
INH test strips, Becton Dickinson, Cowley, United King-
dom) or dipsticks made in any laboratory.4
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Dr. Small replies:
To the Editor: I appreciate the valid comments made by
each of the correspondents, the spectrum of which em-
phasizes the complexities of managing tuberculosis in the
current era. Some of this complexity arises from the intrin-
sic challenges of translating treatment guidelines into clini-
cal practice. For example, Mr. Leiner asks whether, given
the de-emphasis of age as a criterion for treating latent tu-
berculosis infection, I would “prescribe isoniazid to a re-
cently arrived 75-year-old” immigrant. Perhaps, depending
on the details. In general, I might not, but I certainly would
if the person were at high risk for progression to active dis-
ease (such persons are a group for which there has never
been an age cutoff ).
An important resource for assistance in working through
the details of specific situations is the “tuberculosis warm-
lines” funded in part by the CDC (415-502-4700 or 800-
4TB-DOCS). Health care providers who dial these num-
bers will be connected within 24 hours to a tuberculosis
expert with whom they may discuss individual situations.
PETER M. SMALL, M.D.
Stanford University Medical Center
Stanford, CA 94305
peter@molepi.stanford.edu
More on Pamidronate in Langerhans’-Cell 
Histiocytosis
To the Editor: Arzoo et al. (July 19 issue)1 report on a
23-year-old woman with Langerhans’-cell histiocytosis and
severe pain due to osteolytic lesions, who had a good re-
sponse to a 90-mg infusion of pamidronate. Although the
literature on the use of pamidronate in patients with Lang-
erhans’-cell histiocytosis is scarce, there have been previous
observations.2-4
Elomaa and coworkers reported that the use of pami-
dronate (1.6 g per day orally for six months) in two adults
with multifocal eosinophilic granuloma resulted in pain re-
lief, regression of lesions, and biochemical evidence of de-
creased bone resorption.2 Recently, my colleagues and I re-
ported our experience in treating a 14-year-old boy who
had long-standing multisystem Langerhans’-cell histiocyto-
sis with multifocal bone pain, which was unresponsive to
chemotherapy, corticosteroids, antiinflammatory agents, and
narcotic analgesics.3 He had a response to two cycles of in-
travenous pamidronate, each of which consisted of 90 mg
per day given on three consecutive days. Two subsequent
episodes of deterioration responded to the same treatment.
The use of bisphosphonates in the treatment of pulmonary
Langerhans’-cell histiocytosis was also recently suggested,
on the basis of their relative safety and their documented
antimacrophage activity.4
R. MAARTEN EGELER, M.D., PH.D.
Leiden University Medical Center
2300 RC Leiden, the Netherlands
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To the Editor: The observation by Arzoo et al. that pam-
idronate therapy was effective in relieving bone pain in their
patient with osteolytic Langerhans’-cell histiocytosis is con-
sistent with both the pharmacologic action of aminobisphos-
phonates in this context and the biochemistry of Langer-
hans’-cell histiocytosis. Nitrogen-containing bisphosphonates
inhibit the mevalonate pathway, leading to the reduced for-
mation and function of osteoclasts and to their apoptosis.1,2
Thus, one would expect pamidronate to be effective in re-
lieving bone pain in patients with osteolytic Langerhans’-
cell histiocytosis, given the identification of components
of the mevalonate pathway in this disease. Specifically, the
earlier report of a preponderance of cholesterol esters in
histiocytosis X cells3 and my recent detection of the a sub-
unit of both farnesyltransferase and geranylgeranyltransferase
in osteolytic lesions from patients with Langerhans’-cell his-
tiocytosis (Fig. 1) provide evidence of the mevalonate path-
way in osteolytic Langerhans’-cell histiocytosis and support
the reported observation by Arzoo et al.
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Danville, PA 17822-0131
rebrown@geisinger.edu
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Vesical Varices in a Patient with Portal 
Hypertension
To the Editor: Portal hypertension is a frequent conse-
quence of cirrhosis and may lead to dilated venous collat-
erals. Usually, varices due to portal hypertension develop
in the lower esophagus, stomach, or rectum and rarely in
other parts of the digestive tract.1 Extraintestinal ectopic
varices are very rare. We recently treated a patient with cir-
rhosis who had gross hematuria from vesical varices.
A 54-year-old woman with ongoing alcohol abuse had
a sudden onset of profuse gross hematuria. She had a history
of alcoholic liver cirrhosis, complicated by decompensated
ascites and ruptures of esophageal varices, and chronic pan-
creatitis. She had undergone sclerotherapy and band liga-
tion for the management of varices. Her history was also
notable for cholecystectomy, radical left nephrectomy for
renal-cell carcinoma, and hysterectomy. Her hematuria had
stopped by the time she was admitted.
Abdominal ultrasonography showed multiple nonecho-
genic nodes in the superior and posterior wall of the bladder.
Cystoscopy demonstrated large vesical varices (Fig. 1). Selec-
tive angiography of the superior mesenteric artery revealed
venous dilatations at the root of the mesentery, in the ileal
and colonic region, which drained to large vesical varices and
then to the right internal and external iliac veins. The patient
was treated with propranolol, which is used to treat patients
with cirrhosis and variceal hemorrhage. There was no recur-
rence of hematuria during one year of follow-up.
Figure 1. Immunohistochemical Detection of the a Subunit
Common to Farnesyltransferase and Geranylgeranyltransferase
of Human Origin in an Osteolytic Lesion from a Patient with
Langerhans’-Cell Histiocytosis (3-3'Diaminobenzidine Tetrahy-
drochloride Chromogen, ¬788).
The strong staining (brown chromogen) in both the multinucle-
ated, osteoclast-like giant cells and the lesional histiocytes is
indicative of the presence of this antigen in Langerhans’-cell
histiocytosis and, therefore, of the branching point of the me-
valonate pathway,4 which leads to both prenylation of proteins
and cholesterol synthesis.
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Vesical varices secondary to portal hypertension are rare,
since the bladder wall is an unusual collateral route for the
venous splanchnic blood. Vesical varices may appear when
the usual splanchnic-bed collaterals cannot develop,2 thus
allowing venous blood to flow through the venous system
of the bladder. Since our patient had a history of sclerother-
apy, band ligation, and abdominal surgery, her usual venous
collaterals may have been interrupted.
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From a Physician in Lower Manhattan
To the Editor: I have a private practice, with two other
family physicians, in an office in the financial district of low-
er Manhattan, five blocks (300 m) from the site of the World
Trade Center. Most of our patients work or live in lower
Manhattan, including many who worked in the World Trade
Center or its vicinity. We have learned of the deaths of at
least four of our patients who were trapped in the collapse
of the World Trade Center towers on September 11.
At the time of the attacks, our office had just opened for
the day. (I was on the New York City subway, which had
been stopped shortly after the crash of the first airplane.)
Within minutes after the crash of the second airplane,
when the nature of the attacks became clear, much of lower
Manhattan, including our office, was evacuated. There was
considerable fear and anxiety, particularly about the pros-
pect of further attacks, but everyone was evacuated safely.
Federal and city authorities kept lower Manhattan evac-
uated, except for emergency personnel, for six days after the
attacks. Electricity and telephone service remained disrupt-
ed, and sanitation crews cleaned tons of debris and thick
dust from the streets and building facades. We kept in touch
with many of our patients by means of an e-mail list we
maintain. Patients contacted me by e-mail, as well as by tele-
phone, at our satellite office in midtown Manhattan. A state
of shock and grief pervaded New York in the first weeks
after the tragedy. The most common requests from patients
were for refills of existing prescriptions. Many patients had
been evacuated from their homes and had left their med-
ications behind. Others depended on pharmacies that were
closed. One popular pharmacy was destroyed in the col-
lapse of the buildings.
During the second week after we had reopened our of-
fice, the psychic consequences of the tragedy became clear
in the problems our patients reported. Many reported in-
somnia, difficulty concentrating, nightmares, fear of reenter-
ing the vicinity of the attacks, and tearfulness. Most accepted
prescriptions for antidepressants, anxiolytic agents, and hyp-
notic agents. Many accepted referrals to mental health pro-
fessionals, who were overwhelmed with calls but remained
available during the crisis. Somatic manifestations of post-
traumatic stress were common.
Patients told of narrow escapes from the buildings, at-
tempts to outrun the thick plume of debris that rapidly
filled the canyon-like streets of New York. They told of wit-
nessing people jump from the tops of the towers, and they
told of seeing bodies and body parts. Others told of the
loss of friends and family members who had worked in the
World Trade Center. One patient lost seven coworkers. An-
other counted among the dead 17 colleagues at the Fuji
Bank in the World Trade Center.
Over a month after the tragedy, New Yorkers are still pre-
occupied with thoughts of the disaster, despite pleas by the
mayor for a return to normalcy. Most of our patients con-
tinue to express their fears, and many continue to experi-
ence depression and anxiety.
The attacks of September 11 were unprecedented. Unfor-
tunately, there is now a lot to learn in lower Manhattan about
the medical and psychiatric consequences of terrorism.
MARK E. HOROWITZ, M.D.
Downtown Family Medicine
42 Broadway
New York, NY 10004
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Figure 1. Cystoscopic Findings Demonstrating Varices on the
Posterior Wall of the Bladder.
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